INTRODUCTION {#S1}
============

Epithelial ovarian cancer is the most aggressive gynecologic malignancy. Ovarian cancer is composed of a diverse group of tumors that can be classified according to their distinctive morphologic and molecular features ([@R1]). Among them, high-grade serous carcinoma represents the major tumor type associated with frequent tumor recurrence and high mortality. In contrast to other subtypes, high-grade serous carcinomas are highly aggressive, evolve rapidly, and almost always present at advanced stage. Several studies have analyzed global DNA copy number alterations specifically in different types of ovarian epithelial carcinomas ([@R2]--[@R8]). The results from these reports indicate that high-grade serous carcinomas are characterized by higher levels of sub-chromosomal gains and losses than clear cell carcinoma, low-grade serous carcinomas, and their precursor lesions, serous borderline tumors. This finding suggests that chromosomal instability is more pronounced in high-grade serous carcinomas than other types of ovarian cancer.

To identify new cancer-associated genes that may participate in the pathogenesis of ovarian high-grade serous carcinoma, we have previously applied digital karyotyping ([@R9]) and, subsequently, SNP arrays to analyze somatic genome-wide DNA copy number alterations in purified ovarian high-grade serous carcinoma samples ([@R2], [@R4], [@R10]). As a result, in addition to several previously known amplified chromosomal regions containing *CCNE1*, *AKT2*, and *PIK3CA* loci, we identified several new amplified loci including chromosome (ch)11q13.5 harboring *Rsf-1* (*HBXAP*) ([@R11]), chr19p13.12 harboring *NOTCH3* ([@R12]), and regions at chr12p13, chr8q24 and chr19p13.2. Those regions containing known tumor-associated genes were validated using dual color fluorescence in situ hybridization (FISH) in an independent set of ovarian carcinomas ([@R4]). The purpose of this report is to study a previously uncharacterized amplified region at ch19p13.2. Based on digital karyotypic analysis in a limited set of clinical samples, we detected a discrete amplicon located at ch19p13.2 which has not been previously reported in ovarian cancer. This amplicon appears to be relatively large, encompassing 1.92 Mb and containing at least 60 coding sequences, which poses challenges for further investigation to identify the cancer "driver" gene(s) within this amplified region. Several genome database resources such as The Cancer Genome Atlas (TCGA) have recently become available for public access, providing a hitherto unavailable opportunity for molecular genetic discovery in cancer. In this study, we take the advantage of the emerging dataset of the TCGA to simultaneously analyze mRNA and genomic DNA copy numbers for all genes within the digital karyotyping-defined ch9p13.2 amplicon in a large set of high-grade serous carcinomas. This approach enabled us to distinguish cancer "driver" genes from co-amplified "passenger" genes. We then validated our results using fluorescence *in situ* hybridization and immunohistochemistry in an independent set of ovarian carcinomas.

MATERIALS AND METHODS {#S2}
=====================

Analysis of The Cancer Genome Atlas database {#S3}
--------------------------------------------

Copy number variations of the ch9p13.2 amplicon in 343 ovarian tumor samples and paired normal samples were characterized using the Affymetrix SNP6.0 array by the Broad Institute (Boston). The intensity and log~2~ ratios for each probe set on the SNP array were downloaded from The Cancer Genome Atlas Data Portal (<http://tcga-data.nci.nih.gov/tcga/>). Somatic copy number alterations were analyzed using the Circular Binary Segmentation (CBS) algorithm ([@R13]) with R package "DNACopy" (version 1.14.0, default setting). Regions with focal somatic copy number alterations were identified by GISTIC analysis in GenePattern ([http://www.broadinstitute.org/cancer/software/ genepattern/](http://www.broadinstitute.org/cancer/software/genepattern/)) ([@R14]). Expression analysis of 377 ovarian tumor samples was performed using the Affymetrix Human Exon 1.0 ST Array by the Lawrence Berkeley Laboratory. The CEL files were downloaded from the TCGA Data Portal. The probe set signals were summarized as RMA scores with Affymetrix Power Tools ([http://www.affymetrix.com/partners_programs/programs/developer/tools/ powertools.affx](http://www.affymetrix.com/partners_programs/programs/developer/tools/powertools.affx)). The locations of all probe sets were obtained from the Affymetrix annotation file (HuEx-1_0-stv2.na29.hg18.probeset.csv). A total of 8,101 core probe sets (representing 590 genes) located at the regions with focal somatic copy number alterations were selected for expression-copy number correlation analysis. Copy number data and exon-array data were available for 341 cases; therefore this sample set was used for analysis in this study. For these samples, Pearson correlation coefficients were calculated using the expression of each probe set and its corresponding copy number across the 341 cases. The distribution of correlation coefficients of all 8,101 probe sets is bimodal, separating the genes (probe sets) with no correlation (correlation coefficient below 0.2) from those that show correlations between DNA copy number and RNA expression.

Fluorescence *in situ* hybridization {#S4}
------------------------------------

A total of 175 ovarian high-grade serous carcinomas were analyzed for DNA copy number within the ch19p13.2 region using two-color fluorescence in situ hybridization (FISH). Stage III or IV tumor tissues from patients treated at the Johns Hopkins Hospital were originally retrieved from the Department of Pathology at the Johns Hopkins Hospital. The acquisition of the anonymous tissue specimens for this study was approved by the Johns Hopkins Institutional Review Board. The tissues were arranged in tissue microarrays to facilitate FISH and immunohistochemistry procedures. BAC clones (RP11-356L15 and CTD-2508D10) containing the genomic sequences of the ch19p13.2 amplicon were purchased from Bacpac Resources (Childrens\' Hospital, Oakland, CA) and Invitrogen (Carlsbad, CA). Bac clones located at ch19p12 (CTD-2518O18) were used to generate reference probes. The method for FISH was previously described ([@R15]). The hybridization signals were counted by two individuals. Signal ratios of experimental probe/reference probe greater than 2.5 were considered as gain, and signal ratios of experimental probe/reference greater than 3.5 were considered as high-fold amplification. At least 50 nuclei were counted for each specimen.

Immunohistochemistry {#S5}
--------------------

The NAC1 mouse monoclonal antibody used for immunohistochemistry was purchased from Novus Biologicals (Littleton, CO). The specificity of the antibody was previous demonstrated ([@R16]). Paraffin sections from the same tissue microarrays as used for FISH were deparaffinized and pretreated with low pH citrate buffer in a microwave oven for antigen retrieval. Tissue sections were incubated with the anti-NAC1 antibody at a dilution of 1:100 at 4°C overnight. Visualization was performed using the EnVision™+ peroxidase system (DakoCytomation, Glostrup, Denmark). Positive controls consisted of an ovarian carcinoma shown to be positive in a pilot study. Negative controls were stained with an isotype-matched mouse myeloma protein. Immunoreactivity was scored by two investigators who were blinded to the patient clinical data. Nuclear localization was interpreted as positive staining. Staining intensity was scored on a scale of 0--3, corresponding to undetectable, weak, moderate, and intense immunoreactivity in tumor cells ([@R16]). At least 500 tumor cells were counted for each specimen.

RESULTS {#S6}
-------

As a continuing effort to understand the molecular etiology of ovarian cancer, we have previously analyzed DNA copy number changes in different types of ovarian carcinoma. Based on digital karyotyping ([@R9]) in affinity-purified, high-grade ovarian serous carcinomas, we detected a discrete, novel amplified region located at ch19p13.2 in one of 7 specimens ([Fig. 1A](#F1){ref-type="fig"}). This amplified locus was estimated to have \~17 copies of haploid genome and spanned 12,735,244 to 14,655,263, containing at least 60 genes. Based on this preliminary finding, we decided to determine the frequency of increased copy number at this region in a large set of high-grade serous carcinomas. First, we analyzed DNA copy number in 341 high-grade serous carcinomas from the TCGA ovarian cancer genome dataset. The results indicated that 18% of 341 high-grade serous carcinomas showed increased DNA copy numbers (\>2.5) based on SNP arrays. If a higher cutoff value (\>3.5) was applied, the fraction of amplified cases was 3%. To identify potential cancer "driver" genes within the ch19p13.2 amplicon, we correlated mRNA expression levels and DNA copy number at a genome wide scale in the same set of carcinomas. The rationale for this analysis is that, when amplified, "driver" genes almost always upregulate their expression, which enables their oncogenic functions. Based on this analysis, we listed the top 100 amplified genes with the highest correlation coefficient between DNA copy number and mRNA expression levels (as determined by Pearson correlation analysis ([Table 1](#T1){ref-type="table"}). Using this approach, we identified several amplicons harboring well-known amplified oncogenes, including *CCNE1* ([@R17]), *AKT2* ([@R18]), *Pak1* ([@R5]), *Rsf-1* ([@R19]) and *Paf1* ([@R20]). Interestingly, chromosome 19 contained a very high number of candidate driver oncogenes. Among the top 100 genes, 54 genes were located at discrete subchromosomal regions of chromosome 19, indicating that frequent structural re-arrangement may occur in this chromosome in high-grade ovarian serous carcinoma ([Fig. 1B](#F1){ref-type="fig"}). Importantly, the ch19p13.2 region harbored 7 genes which showed the most significant correlation between DNA copy number and RNA expression level.

To validate the above results obtained from *in silica* analysis, we applied two-color FISH and immunohistochemistry to an independent set of tumors composed of 175 high-grade serous carcinomas collected at our institution. We focused on one of the 7 candidate "driver" genes at ch19p13.2, *NACC1*, because as compared to the other 6 genes, the biological role of *NACC1* has been previously reported. NAC1, encoded by *NACC1*, is a nuclear protein involved in stemness of embryonic stem cells ([@R21]) and in the pathogenesis of human cancer ([@R16]). NAC1 has been demonstrated to participate in the development of chemoresistant recurrent tumors ([@R22], [@R23]). In this study, we further determined if amplification of the *NACC1* locus was related to early disease recurrence in high-grade ovarian serous carcinomas. We designed FISH probes that hybridized to the *NACC1* coding region and found that 35 (20%) of 175 carcinomas demonstrated gene copy number gain (\> 2.5) at ch19p13.2. Furthermore, 8 (5%) of 175 tumors exhibited high level amplification (\>3.5) in DNA copy number at this locus. An example of FISH in a high-grade serous carcinoma is shown in [Fig. 2](#F2){ref-type="fig"}. Immunohistochemistry was used to estimate semi-quantitatively the protein expression levels of NAC1 based on immunostaining intensity in the same set of 175 tumor tissues. We observed that amplified tumors exhibited a significantly higher level of NAC1 expression than those without amplification (p\< 0.005, Fisher\'s exact test). As shown in [Table 2](#T2){ref-type="table"}, the percentage of tumors with an immunostaining score of 3+ was 63%, 26%, and 13% in specimens showing high amplification, low level gain, and no amplification at the *NACC1* locus, respectively. NAC1 immunoreactivity in representative amplified and non-amplified tumors is shown in [Fig. 2B](#F2){ref-type="fig"}.

Next, we asked whether *NACC1* amplification was associated with amplification of other chromosomal loci, including *CCNE1*, *RSF1*, *NOTCH3*, *AKT2*, and *PIK3CA*, which were frequently amplified in high-grade serous carcinoma ([@R4]). The FISH results from the above genes were available in 146 cases and they were used for the correlation study. Based on FISH data and analysis using a 2×2 contingency table, we found that among these genes amplification of only the *NOTCH3* locus (ch19p13.12) was significantly correlated with amplification at the ch19p13.2 locus (*p* = 0.0044) ([Table 3](#T3){ref-type="table"}). Among 175 high-grade serous carcinomas, we identified a subset of 52 primary tumors from patients whose follow-up information was available. These patients were selected also based on their similar clinical treatment outcome including optimal cytoreductive surgery (residual tumor\< 0.5 cm) followed by a similar regimen of carboplatin/paclitaxel therapy at the Johns Hopkins Hospital, Baltimore, Maryland. We observed that an increase in DNA copy number in the *NACC1* locus significantly correlated with earlier recurrence (within 6 months after diagnosis) compared with those without amplification (p= 0.013) ([Table 4](#T4){ref-type="table"}).

DISCUSSION {#S7}
==========

In this study, we provide new evidence that DNA copy number at the ch19p13.2 subchromosomal region is increased in approximately one fifth of high-grade serous carcinomas. This finding is based on two large independent cohorts, using two independent techniques including SNP arrays and FISH. The frequency of ch19p13.2 amplification is comparable to that at the *CCNE1*, *NOTCH3*, *RSF1*, *AKT2*, and *PIK3CA* loci which were found to be amplified in 36%, 32%, 16%,14%, and 11% of high-grade serous carcinomas, respectively ([@R4]). However, it is uncertain whether ch19p13.2 represents a discrete amplicon or a continuum of a larger region of DNA copy number gain in ch19p, perhaps involving the whole arm. The significant co-amplification event of ch19p13.2 and the *NOTCH3* locus (ch19p13.12) suggests such a possibility given the proximal location of both loci. Nevertheless, based on our FISH and immunohistochemistry analysis of the same tumor samples, NAC1 expression likely depends on amplification within the ch19p13.2 amplicon. The above results have several important implications with respect to molecular genetic changes and pathogenesis of tumor recurrence in ovarian cancer.

To determine the significance of amplified genes in human cancer, we applied an approach based on the rationale that a tumor-driving gene, when amplified, is almost always over-expressed, which activates the oncogenic pathway, while co-amplified "passenger" genes that are unrelated to tumor pathogenesis may or may not be over-expressed ([@R24]). Therefore, we analyzed all genes within all amplified regions detected by the TCGA ovarian cancer dataset to correlate DNA and transcript copy numbers within the same tumor samples. As a result, we have identified 100 genes with the most significant correlation between DNA copy numbers and RNA expression levels and have found that several ovarian cancer-associated oncogenes were on the list, including *CCNE1* ([@R17]), *AKT2* ([@R18]), *Pak1* ([@R5]), *Rsf-1* ([@R19]), and *Paf1* ([@R20]). This finding, together with the data showing *CCNE1* as the most frequently amplified region (copy number \> 3.5) in ovarian serous carcinoma, supports the robustness of this approach in identifying potential cancer driver genes within amplicons. From this perspective, we found that *NACC1* was listed with an R value as high as 0.558. This finding suggests that *NACC1* is one of the genes that contribute to tumor progression in ovarian cancer in which ch19p13.2 amplification is found. Of note, analysis of the 100 top gene list reveals that the majority of the amplified ovarian cancer driver genes are located on three chromosomes, 8, 11, and 19, a finding consistent with our previous FISH study that profiled all amplicons in ovarian serous carcinoma ([@R4]). This information may provide a potential roadmap to study the pathogenesis of ovarian serous carcinoma in the future.

The association of the ch19p13.2 amplification and shorter disease relapse time may be related to NAC1 overexpression. NAC1, encoded by *NACC1*, belongs to the BTB/POZ domain gene family and contains the BTB/POZ domain, which is responsible for homodimerization and heterodimerization with other BTB/POZ proteins as well as the BEN domain that mediate protein-DNA and protein-protein interactions during chromatin organization and transcription ([@R25]). The role of NAC1 in the development of human cancer has recently emerged. NAC1 is significantly overexpressed in several types of human cancers including ovarian high-grade serous carcinoma ([@R16], [@R22], [@R26], [@R27]), endometrial carcinoma ([@R28]), and cervical carcinoma ([@R29]). Like several BTB/POZ family members, NAC1 proteins homo-dimerize through the BTB domain. Induced expression of a NAC1 deletion mutant (N130) containing exclusively the BTB domain attenuates the tumor-promoting functions of NAC1 ([@R16]). On the other hand, over-expression of full-length NAC1 is sufficient to enhance tumorigenicity of ovarian surface epithelial cells and NIH3T3 cells in athymic *nu/nu* mice ([@R16]). More recently, we observed that enforced expression of NAC1 conferred drug resistance, and NAC1 knockdown by shRNA sensitized paclitaxel cytotoxicity in ovarian cancer cells *in vitro* ([@R22]). NAC1 contributed to the development of drug resistance through multiple mechanisms including upregulating fatty acid synthase ([@R30]) and negatively regulating the components of the Gadd45 tumor suppressor pathway including Gadd45α and its binding protein, Gadd45gip1 ([@R22], [@R26]). The above findings may explain the clinical observation that upregulation of NAC1 immunoreactivity in primary ovarian tumors is associated with aggressive clinical behavior and tumor recurrence in ovarian cancer patients ([@R16], [@R27]). We did not attempt to analyze the clinical correlation of *NACC1* amplification using the TCGA dataset because of concerns about the difference in treatment regimens and patient populations from the various institutions that contributed to the dataset.

The frequent co-amplification of the *NACC1* and *NOTCH3* is of interest. Our previous studies showed amplification of the *NOTCH3* locus in 32% of ovarian high-grade serous carcinomas ([@R12]), and Notch3 overexpression is related to the recurrence of ovarian cancer and confers drug resistance ([@R31]). Ovarian cancer cells which had amplified and overexpressed Notch3 were dependent on Notch3 signaling for cellular survival and growth. Thus, it is likely that increased DNA copy number in both genes may contribute to the resistance of carboplatin and paclitaxel that are routinely used in treating advanced stage ovarian cancer patients. Interestingly, we have recently demonstrated that inactivation of the Notch3 pathway led to inhibition of NAC1 expression, indicating that Notch3 signaling may regulate the expression of NAC1 ([@R31]). Further studies are required to confirm the molecular cross talk between these pathways in the development of chemoresistance.

In summary, based on analysis of the TCGA ovarian cancer dataset and our FISH result, we were able to demonstrate that amplification at the *NACC1* locus was one of the frequent molecular genetic alterations in ovarian high-grade serous carcinomas. NAC1 overexpression may be, in part, attributed to the increase in DNA copy number, explaining why amplification at the *NACC1* locus is related to early tumor recurrence in ovarian cancer. Future studies should aim at fine mapping the ch19p13.2 amplified region and assessing the potential of other genes at the ch19p13.2 locus to contribute to the aggressive behavior of ovarian serous carcinomas that harbor this amplification.
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![Amplification at the ch19p13.2 region harboring *NACC1*. **A.** A focused view of the digital karyotyping result demonstrates a discrete amplicon spanning from nucleotide position 12,735,244 to 14,655,263 in a high-grade serous carcinoma. *NACC1* is located within the amplicon. **B.** Analysis of the TCGA ovarian cancer dataset reveals 100 top genes showing the highest correlation coefficient between DNA copy number and RNA expression levels. Among them, 54 genes are located on chromosome 19. Their physical map is shown. Of note, three amplified chromosomal regions, 19p13.2, 19q12, and 19q13.1--19q13.2 harbor *NACC1*, *CCNE1* and *AKT2*, respectively.](nihms-255771-f0001){#F1}

![DNA copy number at the *NACC1* locus and NAC1 immunoreactivity from representative high-grade serous carcinomas. **A.** Two-color fluorescence *in situ* hybridization in two high-grade serous carcinomas shows increased signal of the ch19p13.2 probe (red fluorescence) whereas the control probe (green fluorescence) that hybridizes to a region near the ch19p12 does not shown any gain of intensity. The case on the left panel shows discrete red probe signals whereas the case on the right shows the homogeneously staining regions. The ideogram on the left illustrates the locations which hybridize to the ch19p13.2 probe (red bar) and to the ch19p12 control probe (green bar). **B:** Immunohistochemistry of NAC1. High-grade ovarian serous carcinomas with high levels of ch19p13.2 amplification show intense immunostaining (3+) of NAC1 in the nuclei (top panels). High-grade ovarian serous carcinomas without detectable alteration of DNA copy number at the ch19p13.2 show variable immunostaining intensity with staining scores ranging from 0 to 2+ (bottom panel). Immunostaining scores are indicated in each photomicrograph.](nihms-255771-f0002){#F2}

###### 

The top 100 amplified potential "driver" genes in ovarian high-grade serous carcinomas[\*](#TFN1){ref-type="table-fn"}.

  Gene       Chr     Start       End         correlation   *f*CN\> 2.5   *f*CN\> 3.5
  ---------- ------- ----------- ----------- ------------- ------------- -------------
  MRPS15     chr1    36693996    36702545    0.54          0.157         0.017
  NDUFS5     chr1    39264593    39272842    0.548         0.190         0.029
  NFYC       chr1    40950961    41009843    0.555         0.201         0.029
  CTPS       chr1    41221558    41250797    0.561         0.201         0.026
  ANKRD17    chr4    74159477    74262083    0.544         0.055         0.020
  TAF2       chr8    120812677   120914224   0.551         0.475         0.050
  DERL1      chr8    124095009   124123533   0.674         0.484         0.055
  C8orf76    chr8    124301438   124322767   0.545         0.487         0.061
  FAM91A1    chr8    124849893   124894217   0.547         0.490         0.067
  TRMT12     chr8    125532260   125534217   0.585         0.501         0.073
  RNF139     chr8    125556194   125569280   0.609         0.501         0.073
  TATDN1     chr8    125569937   125600266   0.573         0.504         0.073
  NDUFB9     chr8    125620609   125631394   0.67          0.507         0.076
  SQLE       chr8    126080726   126103690   0.566         0.510         0.085
  KIAA0196   chr8    126105711   126173112   0.563         0.510         0.082
  NSMCE2     chr8    126173357   126448429   0.577         0.513         0.082
  FAM84B     chr8    127633871   127639562   0.534         0.539         0.085
  TRAPPC9    chr8    140742588   141468678   0.53          0.487         0.061
  EIF2C2     chr8    141610518   141714814   0.552         0.504         0.079
  PTK2       chr8    141738135   142080483   0.594         0.519         0.093
  TSTA3      chr8    144765938   144770015   0.592         0.464         0.055
  ZNF623     chr8    144802992   144809553   0.54          0.466         0.055
  PUF60      chr8    144970693   144983194   0.589         0.472         0.055
  EXOSC4     chr8    145133522   145135551   0.526         0.469         0.055
  GPAA1      chr8    145209555   145213055   0.546         0.469         0.055
  CYC1       chr8    145222009   145224324   0.636         0.469         0.055
  MAF1       chr8    145231324   145234469   0.554         0.472         0.055
  DGAT1      chr8    145510769   145521317   0.54          0.478         0.050
  CPSF1      chr8    145589295   145605344   0.544         0.481         0.055
  CYHR1      chr8    145660034   145661276   0.61          0.481         0.055
  RPL8       chr8    145986002   145988284   0.589         0.461         0.050
  ZNF7       chr8    146025232   146039406   0.55          0.461         0.050
  C8orf33    chr8    146277824   146281416   0.532         0.443         0.058
  UVRAG      chr11   75268572    77468762    0.538         0.187         0.012
  PRKRIR     chr11   75744310    75740093    0.56          0.184         0.023
  C11orf30   chr11   75835631    75939155    0.584         0.190         0.026
  PAK1       chr11   76721458    76781171    0.581         0.213         0.029
  CLNS1A     chr11   77004989    77026476    0.638         0.222         0.029
  RSF1       chr11   77055016    77056050    0.558         0.224         0.032
  C11orf67   chr11   77209888    77261043    0.56          0.222         0.032
  INTS4      chr11   77306760    77306854    0.542         0.227         0.032
  NDUFC2     chr11   77457655    77468762    0.537         0.233         0.035
  ALG8       chr11   77489671    77528282    0.612         0.233         0.035
  TM7SF3     chr12   27018069    27058508    0.55          0.248         0.023
  MED21      chr12   27066787    27073856    0.585         0.248         0.023
  CCDC91     chr12   28410133    28703099    0.528         0.222         0.020
  ZNF136     chr19   12134940    12159758    0.541         0.169         0.020
  ZNF564     chr19   12497231    12500487    0.537         0.172         0.026
  ZNF791     chr19   12582753    12601047    0.605         0.169         0.023
  C19orf56   chr19   12639907    12640414    0.672         0.175         0.023
  MORG1      chr19   12645066    12647612    0.549         0.175         0.023
  DHPS       chr19   12647536    12653522    0.617         0.178         0.023
  FBXW9      chr19   12660756    12668379    0.541         0.178         0.023
  TNPO2      chr19   12671568    12695172    0.603         0.178         0.023
  C19orf43   chr19   12702580    12706471    0.563         0.181         0.020
  ASNA1      chr19   12709344    12719395    0.664         0.181         0.020
  TRMT1      chr19   13076853    13088417    0.55          0.216         0.032
  NACC1      chr19   13108094    13112537    0.558         0.216         0.032
  STX10      chr19   13115892    13122076    0.557         0.216         0.032
  CCDC130    chr19   13723435    13735101    0.605         0.230         0.041
  C19orf53   chr19   13746303    13750255    0.561         0.233         0.041
  DNAJB1     chr19   14486600    14490026    0.585         0.224         0.029
  NDUFB7     chr19   14537895    14543869    0.595         0.227         0.029
  AKAP8      chr19   15464337    15490603    0.529         0.251         0.029
  USE1       chr19   17187243    17191604    0.608         0.207         0.023
  NR2F6      chr19   17203747    17216995    0.542         0.210         0.023
  C19orf62   chr19   17239287    17251013    0.589         0.210         0.023
  UQCRFS1    chr19   34390062    34395865    0.544         0.222         0.070
  POP4       chr19   34797996    34798411    0.747         0.257         0.111
  C19orf12   chr19   34883970    34891160    0.555         0.262         0.117
  CCNE1      chr19   34994774    35007039    0.578         0.268         0.117
  C19orf2    chr19   35125351    35198176    0.745         0.262         0.111
  ZNF507     chr19   37529996    37542468    0.532         0.181         0.035
  ZNF420     chr19   37569382    37620662    0.531         0.172         0.020
  ANKRD27    chr19   37779935    37781120    0.676         0.187         0.038
  CCDC123    chr19   38061790    38154709    0.545         0.175         0.029
  RHPN2      chr19   38161367    38173389    0.572         0.175         0.026
  PEPD       chr19   38569954    38594491    0.539         0.163         0.023
  LSM14A     chr19   39355265    39355508    0.628         0.178         0.023
  UBA2       chr19   39611147    39652626    0.607         0.175         0.023
  ZNF585B    chr19   42368828    42369771    0.547         0.178         0.023
  ZNF383     chr19   42409209    42418811    0.546         0.178         0.020
  SPINT2     chr19   43447250    43474812    0.63          0.190         0.029
  PSMD8      chr19   43557200    43566216    0.642         0.184         0.029
  EIF3K      chr19   43806612    43819425    0.615         0.201         0.029
  ACTN4      chr19   43830180    43912972    0.581         0.201         0.032
  ECH1       chr19   43997942    44014245    0.715         0.195         0.035
  SIRT2      chr19   44061065    44061778    0.535         0.204         0.050
  SARS2      chr19   44097752    44113153    0.556         0.201         0.050
  SAMD4B     chr19   44539177    44565771    0.6           0.198         0.052
  PAF1       chr19   44568126    44573344    0.718         0.198         0.052
  MED29      chr19   44573856    44582453    0.657         0.195         0.052
  RPS16      chr19   44615726    44618471    0.556         0.195         0.052
  SUPT5H     chr19   44628301    44659054    0.641         0.190         0.052
  TIMM50     chr19   44662966    44672833    0.657         0.181         0.052
  FBL        chr19   45016951    45023256    0.597         0.166         0.041
  PSMC4      chr19   45168950    45179137    0.686         0.152         0.035
  AKT2       chr19   45430106    45483092    0.668         0.128         0.023
  SERTAD3    chr19   45638677    45640331    0.539         0.120         0.023
  SHKBP1     chr19   45774650    45789026    0.573         0.111         0.020

These genes showed the best correlation between DNA and copy number and RNA expression levels with R\> 0.526 from the TCGA ovarian cancer dataset. Different chromosomes are indicated by different color highlights. Genes within the chr19p13.2 amplicon are in red fonts.

Chr: chromosome

###### 

Correlation of *NACC1* DNA copy number and staining intensity in 175 high-grade serous carcinomas.

                                                 3+   2+   1+   0    Total
  ---------------------------------------------- ---- ---- ---- ---- -------
  ***NACC1* amplification (copy number\>3.5)**   5    1    2    0    8
  ***NACC1* gain (3.5\> copy number \> 2.5**     7    6    9    5    27
  **Non-amplified**                              18   45   33   45   140
  **Total**                                      30   52   44   50   175

Fisher\'s exact test p= 0.0047

###### 

Co-amplification of *NACC1* and *NOTCH3* loci.

                              *NOTCH3* amplified   *NOTCH3* non-amplified   Total
  --------------------------- -------------------- ------------------------ -------
  ***NACC1* amplified**       15                   10                       25
  ***NACC1* non-amplified**   34                   87                       121
  **Total**                   49                   97                       146

Fisher\'s exact test p= 0.0044

###### 

Correlation of *NACC1* locus amplification and the time to first recurrence.

                              Recur within 6 months   Recur after 6 months   Total
  --------------------------- ----------------------- ---------------------- -------
  ***NACC1* amplified**       6                       10                     16
  ***NACC1* non-amplified**   5                       31                     36
  **Total**                   11                      41                     52

Fisher\'s exact test p= 0.013
